$TPST
Tempest Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041429 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $3.054M
YoY Change -15.3% -2.21%
% of Gross Profit
Research & Development $4.221M $4.416M
YoY Change -29.33% -21.85%
% of Gross Profit
Depreciation & Amortization $88.00K $83.00K
YoY Change -56.22% -25.89%
% of Gross Profit
Operating Expenses $4.221M $4.416M
YoY Change -29.33% -21.85%
Operating Profit -$6.592M -$7.470M
YoY Change -24.84% -14.86%
Interest Expense $373.0K $355.0K
YoY Change -4.11% -23.49%
% of Operating Profit
Other Income/Expense, Net -$194.0K -$111.0K
YoY Change 10.23% -71.83%
Pretax Income -$6.790M -$7.581M
YoY Change -24.11% -17.31%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.786M -$7.581M
YoY Change -24.15% -17.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48 -$0.54
Diluted Earnings Per Share -$0.48 -$0.54
COMMON SHARES
Basic Shares Outstanding 13.32M 11.59M
Diluted Shares Outstanding 14.12M 14.10M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.10M $17.60M
YoY Change -74.06% -65.9%
Cash & Equivalents $11.10M $17.60M
Short-Term Investments
Other Short-Term Assets $232.0K $393.0K
YoY Change -75.19% -49.49%
Inventory
Prepaid Expenses $751.0K $292.0K
Receivables
Other Receivables
Total Short-Term Assets $12.29M $18.54M
YoY Change -79.6% -72.87%
LONG-TERM ASSETS
Property, Plant & Equipment $921.0K $1.005M
YoY Change 0.22% -0.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $393.0K $398.0K
YoY Change -42.46% -17.08%
Total Long-Term Assets $11.70M $12.21M
YoY Change 301.37% 301.02%
TOTAL ASSETS
Total Short-Term Assets $12.29M $18.54M
Total Long-Term Assets $11.70M $12.21M
Total Assets $23.99M $30.74M
YoY Change -62.03% -56.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.139M $868.0K
YoY Change 23.14% -40.06%
Accrued Expenses $1.995M $2.454M
YoY Change -22.82% 12.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.134M $2.974M
YoY Change -39.03% 48.7%
Total Short-Term Liabilities $7.422M $8.638M
YoY Change -69.15% -61.48%
LONG-TERM LIABILITIES
Long-Term Debt $8.371M $7.484M
YoY Change -29.28% -43.73%
Other Long-Term Liabilities $9.400M $9.608M
YoY Change 1768.79% 1282.45%
Total Long-Term Liabilities $8.371M $7.484M
YoY Change -29.28% -43.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.422M $8.638M
Total Long-Term Liabilities $8.371M $7.484M
Total Liabilities $25.18M $25.73M
YoY Change -30.83% -29.35%
SHAREHOLDERS EQUITY
Retained Earnings -$157.8M -$151.0M
YoY Change 24.56% 28.26%
Common Stock $14.00K $13.00K
YoY Change 40.0% 30.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.190M $5.012M
YoY Change
Total Liabilities & Shareholders Equity $23.99M $30.74M
YoY Change -62.03% -56.91%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$6.786M -$7.581M
YoY Change -24.15% -17.31%
Depreciation, Depletion And Amortization $88.00K $83.00K
YoY Change -56.22% -25.89%
Cash From Operating Activities -$6.480M -$6.392M
YoY Change -28.57% -24.03%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $117.0K
YoY Change -100.0% -223.16%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$117.0K
YoY Change -100.0% 23.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 1.188M
YoY Change -94.29% -91.74%
NET CHANGE
Cash From Operating Activities -6.480M -6.392M
Cash From Investing Activities 0.000 -117.0K
Cash From Financing Activities 20.00K 1.188M
Net Change In Cash -6.460M -5.321M
YoY Change -26.84% -190.69%
FREE CASH FLOW
Cash From Operating Activities -$6.480M -$6.392M
Capital Expenditures $0.00 $117.0K
Free Cash Flow -$6.480M -$6.509M
YoY Change -27.71% -21.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001544227
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35890
dei Entity Registrant Name
EntityRegistrantName
Tempest Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-1472564
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 Sierra Point Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
dei City Area Code
CityAreaCode
(415)
dei Local Phone Number
LocalPhoneNumber
798-8589
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
TPST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13324065
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17604000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31230000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
450000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
931000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
18535000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
32950000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1005000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10804000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11650000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
398000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
429000
CY2023Q2 us-gaap Assets
Assets
30742000
CY2022Q4 us-gaap Assets
Assets
46089000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
868000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1108000
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
450000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2454000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2023Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
104000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2974000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1414000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1413000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
823000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1248000
CY2023Q2 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
105000
CY2022Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
97000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8638000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7277000
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
263000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
454000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7484000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10371000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9608000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10330000
CY2023Q2 us-gaap Liabilities
Liabilities
25730000
CY2022Q4 us-gaap Liabilities
Liabilities
27978000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12583833
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12583833
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
155988000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153872000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150989000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135772000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5012000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18111000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30742000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46089000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4416000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5651000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9094000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10760000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3054000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3123000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5957000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6175000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7470000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8774000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15051000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16935000
CY2023Q2 us-gaap Interest Expense
InterestExpense
355000
CY2022Q2 us-gaap Interest Expense
InterestExpense
464000
us-gaap Interest Expense
InterestExpense
699000
us-gaap Interest Expense
InterestExpense
797000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
244000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
533000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
73000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-111000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-394000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-166000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-724000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-7581000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-9168000
us-gaap Profit Loss
ProfitLoss
-15217000
us-gaap Profit Loss
ProfitLoss
-17659000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14102211
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14102211
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11573432
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11573432
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13933629
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13933629
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9382515
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9382515
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18111000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
446000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7636000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10965000
CY2023Q2 tpst Stock Issuance Costs
StockIssuanceCosts
30000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1186000
CY2023Q2 tpst Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
440000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7581000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5012000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
36117000
CY2022Q1 tpst Stock Issuance Costs
StockIssuanceCosts
44000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1403000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
328000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8491000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29357000
CY2022Q2 tpst Stock Issuance Costs
StockIssuanceCosts
343000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7095000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
367000
CY2022Q2 tpst Warrant Issuance Costs
WarrantIssuanceCosts
283000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7281000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9168000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
34932000
us-gaap Profit Loss
ProfitLoss
-15217000
us-gaap Profit Loss
ProfitLoss
-17659000
us-gaap Depreciation
Depreciation
208000
us-gaap Depreciation
Depreciation
220000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
886000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
695000
tpst Noncash Lease Expense
NoncashLeaseExpense
846000
tpst Noncash Lease Expense
NoncashLeaseExpense
613000
tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
96000
tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
232000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-370000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-447000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-240000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
438000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-931000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
323000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
8000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
9000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-721000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-839000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14695000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15521000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
163000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-163000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-98000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1232000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8498000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1232000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15779000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13626000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
160000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31598000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51829000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17972000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51989000
us-gaap Interest Paid Net
InterestPaidNet
604000
us-gaap Interest Paid Net
InterestPaidNet
556000
us-gaap Income Taxes Paid
IncomeTaxesPaid
104000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
884000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
4000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17600000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2023Q2 us-gaap Depreciation
Depreciation
83000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p>
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
292000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
703000
CY2023Q2 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
246000
CY2022Q4 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
304000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
393000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
263000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
931000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2570000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2421000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1565000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1361000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1005000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12583833
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12583833
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
us-gaap Depreciation
Depreciation
208000
CY2022Q2 us-gaap Depreciation
Depreciation
112000
us-gaap Depreciation
Depreciation
220000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1003000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
756000
CY2023Q2 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
1451000
CY2022Q4 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
2205000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2454000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
10500000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1553041
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
679150
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.29
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
413
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44075
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.58
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2187703
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
790637
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
893527
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34703
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
428.76
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1649461
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.72
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2187703
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2187703
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y6M7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.04
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
24000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
793765
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.98
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
440000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
367000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
886000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
695000
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
35000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
92000
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
37000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
61000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7581000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9168000
us-gaap Net Income Loss
NetIncomeLoss
-15217000
us-gaap Net Income Loss
NetIncomeLoss
-17659000
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14102211
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
11573432
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13933629
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
9382515
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14102211
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14102211
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11573432
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11573432
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13933629
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13933629
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9382515
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9382515
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2193739
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1655497

Files In Submission

Name View Source Status
0000950170-23-041429-index-headers.html Edgar Link pending
0000950170-23-041429-index.html Edgar Link pending
0000950170-23-041429.txt Edgar Link pending
0000950170-23-041429-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tpst-20230630.htm Edgar Link pending
tpst-20230630.xsd Edgar Link pending
tpst-ex10_1.htm Edgar Link pending
tpst-ex10_2.htm Edgar Link pending
tpst-ex10_3.htm Edgar Link pending
tpst-ex10_4.htm Edgar Link pending
tpst-ex31_1.htm Edgar Link pending
tpst-ex31_2.htm Edgar Link pending
tpst-ex32_1.htm Edgar Link pending
tpst-20230630_def.xml Edgar Link unprocessable
tpst-20230630_lab.xml Edgar Link unprocessable
tpst-20230630_pre.xml Edgar Link unprocessable
tpst-20230630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tpst-20230630_cal.xml Edgar Link unprocessable